What is ZetrOZ Systems?
ZetrOZ Systems is a prominent innovator in regenerative technologies, specializing in the development and manufacturing of wearable medical devices. These devices leverage sustained acoustic medicine (sam) to accelerate tissue healing and alleviate pain associated with chronic musculoskeletal conditions. With a robust portfolio of over 46 patents and collaborations with federal research entities, ZetrOZ Systems is committed to advancing healthcare through clinically proven, non-invasive solutions. The company's product line is recognized through major sports medicine partnerships and aims to positively impact the lives of 100 million people. Operating multiple manufacturing facilities in the USA, ZetrOZ ensures the highest standards of quality and efficacy for its offerings.
How much funding has ZetrOZ Systems raised?
ZetrOZ Systems has raised a total of $11.5M across 3 funding rounds:
Private Equity
$4.5M
Private Equity
$2M
Debt
$5M
Private Equity (2012): $4.5M, investors not publicly disclosed
Private Equity (2014): $2M led by Mass Medical Angels, Connecticut Innovations, Boston Harbor Angels, and Launchpad Venture Group
Debt (2014): $5M supported by Horizon Technology Finance Corporation
Key Investors in ZetrOZ Systems
Mass Medical Angels
Mass Medical Angels is a seed-stage investor group focused on life science and healthcare investments, providing financing and mentoring to early-stage companies in medical devices, therapeutics, and diagnostics.
Connecticut Innovations
Connecticut Innovations is the state's strategic venture capital arm, offering equity and debt financing, strategic guidance, and connections to help innovative companies in sectors like biosciences scale.
Boston Harbor Angels
Boston Harbor Angels is an angel investment group supporting early-stage companies in information technology and life sciences, providing financial backing and valuable expertise.
What's next for ZetrOZ Systems?
The recent major strategic investment signifies a pivotal moment for ZetrOZ Systems, likely enabling the company to accelerate its product development pipeline, expand its market reach, and further solidify its presence in the competitive medical device industry. This capital infusion is expected to fuel growth initiatives, potentially including enhanced manufacturing capabilities, broader clinical trials, and expanded distribution networks. The company's focus on patented, non-invasive regenerative technologies positions it for continued expansion and innovation in addressing chronic pain and tissue healing.
See full ZetrOZ Systems company page
